CEO of Otsuka North America: Are We Getting better access with AI?
In an interview, Rabah talked about the promise of AI, where it can have the most impact, while also responding to the IRA and high drug prices in the United States.
What Might the Future of Prescription Drugs Look Like Under Trump?
Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
MedCity Pivot Podcast: Chat With Shawn Gremminger About Employer-Led Healthcare
How are employers tackling the current landscape of healthcare costs? We turned to Shawn Gremminger, CEO of the National Alliance of Healthcare Purchaser Coalitions, a group of regional coalitions representing self-insured employers large and small that cover roughly 40 million people.
Where Trump & Harris Stand on Payers, AI, Drug Pricing and CMS
Experts from BRG recently discussed the two presidential candidates' stances on key healthcare issues, including drug pricing, Medicaid and AI.
Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs?
If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. Hear who else is to blame from the CEO of Blue Shield of California.
Video: Why the FTC’s Lawsuit Against PBMs May Have Some Legs
Months before the FTC sued the three largest pharmacy benefit managers, the CEO of Blue Shield of California battled its PBM - CVS Caremark - to bring a lower cost prostate cancer drug to its members.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
For Big Pharma, Trump vs. Harris Is a Clash Between Two Industry Foes
The industry is increasingly under attack by lawmakers from both parties for drug prices most Americans regard as unreasonable, so the election outcome could be pivotal to drug companies’ fortunes.
Three Ways Drug Pricing Should Work in a Functioning Market, But Isn’t
We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.
How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs
Three things drug manufacturers and CEs can do to build trust and enable effective collaboration
The Senate Attacks on Pharma Put the Industry in Jeopardy and Consumers at Risk
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Health Executives on Digital Transformation in Healthcare
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
presented by
Unlocking Transparency in PBM Pricing
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency.
Don’t Let Inflation Bloat Your Drug Spending
Smart but easy tech upgrades can boost margins.
MedCity News Launches Debunked, A Show Where We Slaughter Myths, Bad Practices and Sacred Cows in Healthcare
MedCity News is launching a new ongoing show called Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare. In this show, co-hosts Arundhati Parmar and Samir Batra will discuss healthcare news and call out things that seem utterly insane to us. The goal is to inspire change in the healthcare industry.
Pharma Just Increased the Price of Hundreds of Drugs. PBMs are Minimizing the Impact for Health Plans, Employers and Patients
While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.
Healthcare Docket: Will Florida’s Plan to Import Drugs From Canada Open the Floodgates?
No matter the outcome, it’s certain that the cost of drugs will not be an issue easily resolved anytime soon even though several other states also have laws allowing for drug imports.